The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and consumer-focused market.

Novo Nordisk, which produces Wegovy and Ozempic, said roughly 9,000 roles would be cut, with 5,000 of these reductions expected in Denmark.

El fabricante del Ozempic señala que Dinamarca será el país más afectado. La compañía acaba de nombrar a un nuevo CEO